Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jiwen Fan, Meng Ren, Binay Kumar Adhikari, Haodong Wang & Yuquan He. (2022) The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis. Journal of Inflammation Research 15, pages 3847-3858.
Read now
Read now
Articles from other publishers (5)
Yi Zhong, Xin-yue Li, Tian-jun Liang, Bao-zhu Ding, Ke-xin Ma, Wen-xuan Ren & Wen-jie Liang. (2024) Effects of NLRP3 Inflammasome Mediated Pyroptosis on Cardiovascular Diseases and Intervention Mechanism of Chinese Medicine. Chinese Journal of Integrative Medicine.
Crossref
Crossref
Xiaolin Liao, Yuanshan Han, Chuanpu Shen, Jianjun Liu & Yuhong Wang. (2023)
Targeting the
NLRP3
inflammasome for the treatment of hypertensive target organ damage: Role of natural products and formulations
. Phytotherapy Research 37:12, pages 5622-5638.
Crossref
Crossref
Mengnan Liu, Xingru Long, Jie Xu, Mingtai Chen, Huayi Yang, Xin Guo, Junli Kang, Yue Ouyang, Gang Luo, Sijin Yang & Hua Zhou. (2022) Hypertensive heart disease and myocardial fibrosis: How traditional Chinese medicine can help addressing unmet therapeutical needs. Pharmacological Research 185, pages 106515.
Crossref
Crossref
Natalia V. Naryzhnaya, Leonid N. Maslov, Sergey V. Popov, Alexandr V. Mukhomezyanov, Vyacheslav V. Ryabov, Boris K. Kurbatov, Alexandra E. Gombozhapova, Nirmal Singh, Feng Fu, Jian-Ming Pei & Sergey V. Logvinov. (2022) Pyroptosis is a drug target for prevention of adverse cardiac remodeling: The crosstalk between pyroptosis, apoptosis, and autophagy. The Journal of Biomedical Research 36:6, pages 375.
Crossref
Crossref
Gaber El-Saber Batiha, Abdulrahim Gari, Norhan Elshony, Hazem M. Shaheen, Murtala Bello Abubakar, Sherif Babatunde Adeyemi & Hayder M. Al-kuraishy. (2021) Hypertension and its management in COVID-19 patients: The assorted view. International Journal of Cardiology Cardiovascular Risk and Prevention 11, pages 200121.
Crossref
Crossref